Abstract
Introduction: The relationship between serum neurofilament light chain (sNfL) and myelin oligodendrocyte glycoprotein antibody (MOG-Ab) status has not been yet investigated in children with the acquired demyelinating syndrome (ADS).
Objective and Methods: The sNfL levels and MOG-Abs were measured by ultrasensitive single-molecule array and cell-based assay in a cohort of 37 children with ADS and negativity for serum anti-aquaporin 4 (AQP4) antibodies. The sNfL levels were compared in MOG-Ab+/MOG-Ab– and in two subgroups MOG-Ab+ with/without encephalopathy.
Results: About 40% ADS resulted in MOG-Ab+. MOG-Ab+ were younger at sampling (median = 9.8; range = 2.17–17.5 vs. 14.7/9–17; p = 0.002) with lower frequency of cerebrospinal fluid oligoclonal bands positivity (27% vs. 70%; p = 0.013) compared to MOG-Ab–. About 53% of MOG-Ab+ presented encephalopathy at onset, 1/22 of MOG-Ab– (p = 0.0006). Higher sNfL levels (p = 0.0001) were found in MOG-Ab+ (median/range = 11.11/6.8–1,129) and MOG-Ab– (median/range = 11.6/4.3–788) compared to age-matched controls (median/range = 2.98/1–4.53), without significant difference. MOG-Ab+ with encephalopathy resulted significantly younger at sampling (median/range: 4.5/2.17–11.17 vs. 14.16/9.8–17.5; p = 0.004), had higher sNfL levels (median/range:75.24/9.1–1,129 vs. 10.22/6.83–50.53; p = 0.04), and showed a trend for higher MOG-Ab titer (0.28/0.04–0.69 vs. 0.05/0.04–0.28; p = 0.1) in comparison to those without encephalopathy.
Discussion: We confirmed high sNfL levels in pediatric ADS independently from the MOG-Ab status. Encephalopathy at onset is associated more frequently with MOG Ab+ children with higher sNfL levels and MOG titer. These findings suggest a role of acute demyelination in association with axonal damage in the pathogenesis of encephalopathy in pediatric ADS.
Introduction
The occurrence of the first event of acquired demyelinating syndromes (ADS) in children is estimated to be 0.87 (95% CI 0.35–1.40) per 100,000 children per year ().
Anti-myelin oligodendrocyte glycoprotein antibodies (MOG-Abs) have emerged as potential biomarkers useful for the differential diagnosis and reflecting pathogenic mechanisms, disease course, prognosis, and therapeutic response in pediatric patients with ADS (–). Serum neurofilament light chain (sNfL) is a marker of neurodegeneration in several neurological diseases (–).
The NfL is a component of the neuron cytoskeleton and is released in the extracellular space after neuronal cell death (, ).
A significant correlation has been found between cerebrospinal (CSF) and sNfL levels in children with ADS () suggesting that sNfL could be a promising peripheral biomarker for axonal injury.
The MOG-Abs had been demonstrated to activate Ab-dependent cellular cytotoxicity against MOG, located on the myelin surface in the central nervous system, determining demyelination ().
Recent data showed a correlation between clinical/radiological activity, cognitive impairment, and an increase of sNfL levels in pediatric patients with multiple sclerosis (MS) and clinically isolated syndrome (CIS) (, ). High sNfL levels were also found in patients with neuromyelitis optica spectrum disorders (NMOSDs) associated with aquaporin-4 (AQP-4) antibodies () and in patients with the anti-MOG-Ab-associated disorder (MOGAD) () indicating the presence of axonal damage in all these disorders. The overall incidence of MOGAD is 0.16 per 100,000 people, with higher seropositivity in children (0.31/100,000) than in adults (0.13/100,000), especially in patients who have experienced an ADS prior to the age of 10 years (). The most common presenting phenotype of MOGAD is acute disseminated encephalomyelitis in children (40–56%) and optic neuritis (ON) in adults (44%) (). The relationship between MOG-Ab titers and sNfL levels remains an area of active investigation. A recent paper () demonstrated in a series of 38 consecutive adult onset ADS MOG-Ab+ that sNfL levels correlated with attack severity and predicted long-term outcome. The same authors, () more recently, analyzed sNfL levels at onset and during follow-up in 18 adult ADS MOG-Ab+ and showed that sNfL levels predominantly increase at disease onset. To date, the relationship between sNfL levels and MOG-Abs has not yet been investigated in pediatric populations with ADS.
In this study, in a cohort of 37 children with the first event of ADS, we tested sNfL levels in MOG-Ab+ and MOG-Ab– patients, and in two subgroups of MOG-Ab+ subdivided into those with and without encephalopathy. Moreover, we compared demographic, clinical, neuroimaging, and laboratory features between these groups.
Methods
Study Population
Between February 2019 and December 2020, 37 patients (F/M 15/22) younger than 18 years with a first acute event of ADS and negativity for serum anti-AQP4 antibodies (AQP4 antibodies are routinely requested in all children with ADS in our center) were recruited at the Neuropsychiatric Unit and the Paediatric Neurology Unit of University/Hospital Policlinico of Bari. All patients underwent blood sampling at the time of the first presentation before starting any treatment.
All sera were tested for sNfL levels and for the presence and levels of MOG-Abs. An additional group of 20 serum samples from age-matched unaffected controls were also tested for sNfL. Baseline demographic (age and gender), clinical (symptoms at onset classified as ON, brainstem involvement, spinal cord involvement, encephalopathy; monofocal or multifocal onset), MRI (presence of brain and/or spinal cord abnormalities), and laboratory [CSF presence/absence of oligoclonal bands (OB)] features were recorded for all patients.
Serum MOG IgG-Ab Assessment
The MOG-Abs were detected by a cell-based assay (CBA). Briefly, cultured human cells (HEK293 cells) were transfected with a vector coding for the antigen MOG conjugated to GFP and used as substrate in an indirect immunofluorescence assay (). Immunofluorescence was performed on transfected cells cultured on glass coverslips. Cells were exposed to the sample sera for 1 h at room temperature, and serum MOG-IgG was detected on the surface of MOG expressing cells, using goat anti-human 568 Alexa-Fluor conjugated secondary antibodies (Invitrogen, Life Technologies, Carlsbad, CA, USA). In order to evaluate unspecific background staining, we routinely performed serum antibody staining using empty vector transfected cells for both immunoassays. A cover glass containing cells was observed using a DMRXA fluorescence microscope (Leica Microsystems, Wetzlar, Germany) provided with a DFC700T color camera. The antibody titer for MOG-Abs was performed by a ratiometric method () using the cells expressing the fluorescent protein (MOG-GFP). Briefly, for each cell line, the analysis was performed using a 20× objective, and two microscopy fields were randomly chosen. For each field, four different regions containing two to four cells were analyzed. Each region was analyzed, fluorescent intensity was measured with a grayscale, and background subtracted values were given as the ratio of red/green for the MOG antibody titer. Values range 0 for no staining and 1 for maximum antibody binding. Therefore, we defined these values as MOG quantitative ratio (MOGqr).
Serum NfL Assessment
The sNfL levels were determined by an ultrasensitive single-molecule array (Simoa) method using the Quanterix-SRX Analyzer Platform (Quanterix, Lexington MA, USA). Blood samples were collected from each of the participants, centrifuged, and sera divided into aliquots were frozen at −80°C for subsequent use.
The sNfL concentrations were measured via the commercially available SimoaTMNF-light® Advantage Kit (Quanterix, Lexington MA, USA), a Singleplex Assay Kit.
Samples (25 μl of serum was diluted 1:4 in the plate by adding 75 μl of sample diluent in each well) were tested blindly and in duplicate and two quality control (high concentration and low concentration quality control) samples were run, in duplicate as well, on each plate for each run necessary to complete the study. The sNfL concentrations (pg/ml) were calculated using a standard curve made from a sample of known NfL concentrations in triplicate according to the instructions of the manufacturer.
The intra-assay coefficient of variation (CV) values have been calculated by the SRX Analyzer Software (Quanterix Corp. Billerica Massachusetts, US) from technical replicate measures of specimens assayed within a single run.
Statistical Analysis
Statistical analysis was performed by using IBM SPSS, release v.20.0 (IBM Corporation, Armonk, NY, USA). We compared demographic, clinical, neuroimaging, and serological data by the Kruskal–Wallis test, Mann–Whitney test, Wilcoxon rank test, Fisher's exact test, and χ2 test. Correlation between age at sampling and sNfL levels were evaluated by the Spearman test. Statistical significance was defined as a two-sided p < 0.05.
Results
About 15 ADS (40%) resulted MOG-Ab+ and 22 (60%) MOG-Ab–. The median value and range of MOG-Ab was 0.12/0.04–0.69 MOGqr in MOG-Ab+ patients. Demographic, clinical, laboratory, and radiological data of the two cohorts are reported in Table 1. MOG-Ab+ ADS had a significantly lower median age at sampling (median = 9.8; range = 2.17–17.5 vs. 14.7/ 9–17; p = 0.002) and showed a lower frequency of CSF OB positivity (27% vs. 70%; p = 0.013) in comparison to MOG-Ab– ADS. About 53% of MOG-Ab+ patients presented encephalopathy at onset, but only in 1/22 of MOG-Ab– patients (p = 0.0006). A multifocal onset was associated more frequently (53%) in MOG-Ab+ than in MOG-Ab– (27%; p = 0.09) ADS.
Table 1
| ADS MOG-Ab+ | ADS MOG-Ab- | p-value | |
|---|---|---|---|
| Number | 15 | 22 | |
| Female, n (%) | 5 (33%) | 9 (40%) | ns |
| Age at sampling, median (range), years | 9.8/2.17–17.5 | 14.7/9–17 | 0.002 |
| MOG-Ab titre, median (range) | 0.12/0.04–0.69 | / | |
| CSF IgG oligoclonal bands (%) | 4/15 (27%) | 15/22 (70%) | 0.013 |
| Abnormal brain MRI (%) | 11/15 (75%) | 19/22 (87%) | ns |
| Abnormal spinal cord MRI (%) | 9/22 (62%) | 13/22 (59%) | ns |
| Encephalopathy at onset | 8/15 (53%) | 1/22 (4.5%) | 0.006 |
| Optic Neuritis at onset (%) | 7/15 (47%) | 11/22 (50%) | ns |
| Myelitis at onset (%) | 8/15 (53%) | 14/22 (64%) | ns |
| Brainstem at onset (%) | 7/15 (47%) | 7/22 (32%) | ns |
| Multifocal onset | 8/15 (53%) | 6/22 (27%) | 0.09 |
Comparison of baseline demographic, clinical, laboratory and radiological features between pediatric ADS MOG-Ab positive (+) and MOG-Ab negative (–).
Among MOG-Ab– patients who had CSF OB positivity (15/22), nine of them had MRI features typical or suggestive of MS, and these patients fulfilled criteria for a CIS diagnosis ().
Significant (p = 0.0001) higher sNfL levels were found in both MOG-Ab+ (median/range = 11.11/6.8–1,129) and MOG-Ab– (median/range = 11.6/4.3–788) patients compared to age-matched controls (median/range = 2.98 (1–4.53), but no significant difference was found between the two groups (Figure 1). A significant negative correlation was found between age at sampling and sNfL levels in this cohort of pediatric ADS (R = −0.434, p = 0.007) (Figure 2).
Figure 1
Figure 2
When compared MOG-Ab+ patients with (N. 8) and without (N.7) encephalopathy (Table 2), children belonging to the first group resulted significantly younger at sampling (median and range: 4.5/2.17–11.17 vs. 14.16/9.8–17.5; p = 0.004), had higher sNfL levels (median/range: 75.24/9.1–1,129 vs. 10.22/6./6.83–50.53; p = 0.04), and showed a trend for higher MOG-Ab titers (0.28/0.04–0.69 vs. 0.05/0.04–0.28; p = 0.1) in comparison to those without encephalopathy.
Table 2
| ADS MOG+ without Encephalopathy | ADS MOG+ with Encephalopathy | p-value | |
|---|---|---|---|
| Number | 7 | 8 | |
| Gender (F/M) | 2/7 | 3/8 | ns |
| Age at sampling, median (range), years | 14.16 (9.8–17.5) | 4.5 (2.17–11.17) | 0.004 |
| MOG-Ab titre, median (range) | 0.05 (0.04–0.28) | 0.28 (0.04–0.69) | 0.1 |
| sNfL median (range) pg/ml | 10.22 (6.83–50.53) | 75.24 (9.1–1.129) | 0.043 |
Comparison of baseline demographic and laboratory features between MOG-Ab positive (+) ADS with encephalopathy and MOG-Ab positive (+) ADS without encephalopathy.
Figure 3 represents a flowchart for the whole study population.
Figure 3
Discussion
In this study, we assessed for the first time in a pediatric population with a first acute event of ADS, sNfL levels according to MOG-Ab status. By using a sensitive MOG-Ab assay, we identified 40% of MOG-Ab+ patients in a selected cohort of pediatric ADS confirming the results observed in previous similar cohorts (), showing that 30–40% of pediatric ADS were associated with MOG-Ab positivity. MOG-Ab+ children were younger at onset in comparison to the MOG-Ab– patients as reported in a previous study in which about 50% of MOG-Ab+ had <11 years at presentation (). We found a lower frequency of CSF OB positivity (27%) in MOG-Ab+ ADS patients in comparison to MOG-Ab– patients (70%) as found in a previous larger population () showing a frequency of 9.1% of CSF OB positivity in MOG-Ab+ and of 94.6% in MOG-Ab– pediatric MS patients. The frequency of the abnormal brain and spinal cord findings did not differ between the two groups. According to previous studies showing a majority of cases (50%) of monophasic forms of MOGAD manifest as acute disseminated encephalomyelitis, especially in patients under the age of 5–10 years (, , ), in our study, we found encephalopathy was present at onset in 53% of MOG-Ab+ patients and only 1/22 MOG-Ab– (<1%), and MOG-Ab+ patients with encephalopathy resulted significantly younger at sampling than MOG-Ab+ patients without encephalopathy. sNfL levels did not differ between pediatric MOG-Ab+ and MOG-Ab– children, but they resulted significantly higher in both groups compared to age-matched controls, confirming that neuroaxonal damage is a prominent feature in ADS. A significant negative correlation was found, in our cohort of pediatric ADS, between age at sampling and sNfL levels. Earlier studies observed an association between sNfL and age, with higher sNfL levels in younger pediatric MS, and a correlation between age and CSF NfL with the highest levels in younger children with neurologic diseases (). This finding is consistent with histologic observations for pediatric MS lesions, where the amount of acutely damaged axons inversely correlated with the age of patients (). A recent paper () demonstrated in a cohort of 102 pediatric patients with a first acute event of ADS that sNfL levels were higher in children presenting with encephalopathy than in those without encephalopathy symptoms. In the current study, we further demonstrated that in ADS MOG-Ab+ children, encephalopathy is associated with higher sNfL levels and a trend for higher MOG titer. These findings not only confirm the prominent role of axonal damage in the pathogenesis of encephalopathy in pediatric MOGAD () but also suggest a possible associated role of acute demyelination.
The role of local anti-MOG IgG deposits and complement activation in the pathogenesis of EAE and ADS MOG+ is still a matter of debate. Serguera et al. () reported that IgG and C1q were associated with myelin and phagocytic cells in brains with EAE and in biopsies of children with ADS MOG+, suggesting that local anti-MOG IgG deposits and complement activation in the perivenular white matter may play a central role in the pathogenesis of EAE and ADS MOG+, initiating and amplifying demyelination. Another paper () demonstrated that MOG-Abs from most patients require bivalent binding that poorly binds to C1q, questioning the pathogenicity of MOG-Abs is mediated by complement activation. In a more recent study () conducted on immunohistochemically analyzed brain tissue biopsies from 11 patients with MOG-Ab-associated disease and other inflammatory demyelinating diseases, the occurrence of perivascular deposits of activated complements and immunoglobulins was occasionally observed in some MOG-Ab-associated demyelinating lesions even if the frequency was much lower than that in AQP4 antibody-positive NMOSD.
These discordant results indicate the need for further studies to ascertain the role of MOG-Abs in the pathogenesis of MOGAD.
The main limitation of this study concerns the small size of each group, especially the subgroup of ADS MOG+; nonetheless, we provide convergent observations with other larger studies. Clearly, larger cohorts and longitudinal studies in pediatric ADS are needed to better investigate the potential interactions between MOG-Ab titers and sNfL levels.
Publisher's Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Statements
Data availability statement
The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.
Ethics statement
The studies involving human participants were reviewed and approved by Policlinico of Bari Ethical Committee. Written informed consent to participate in this study was provided by the participants' legal guardian/next of kin.
Author contributions
MS and LM had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. MS, LM, AF, and MR study concept and design. MS, FP, LM, and AD drafting of the manuscript. MS, LM, LB, AF, and MR critical revision of the manuscript for important intellectual content. LB statistical analysis. MS, FP, AG, and LM administrative, technical, or material support. All authors acquisition, analysis, or interpretation of data.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1.
YanKBalijepalliCDesaiKGullapalliLDruytsE. Epidemiology of pediatric multiple sclerosis: a systematic literature review and meta-analysis. Mult Scler Relat Disord. (2020) 44:102260. 10.1016/j.msard.2020.102260
2.
WongYYBruijstensALBarroCMichalakZMeliefMJWierengaAFet al. Serum neurofilament light chain in pediatric MS and other acquired demyelinating syndromes. Neurology. (2019) 93:e968–74. 10.1212/WNL.0000000000008057
3.
ReinertMCBenkertPWuerfelJMichalakZRuberteEBarroCet al. Serum neurofilament light chain is a useful biomarker in pediatric multiple sclerosis. Neurol Neuroimmunol Neuroinflammation. (2020) 7:e749. 10.1212/NXI.0000000000000749
4.
ArmangueTOlivé-CireraGMartÃnez-HernandezESepulvedaMRuiz-GarciaRMuñoz-BatistaMet al. Associations of paediatric demyelinating and encephalitic syndromes with myelin oligodendrocyte glycoprotein antibodies: a multicentre observational study. Lancet Neurol. (2020) 19:234–46. 10.1016/S1474-4422(19)30488-0
5.
WatersPFaddaGWoodhallMO'MahonyJBrownRACastroDAet al. Serial anti-myelin oligodendrocyte glycoprotein antibody analyses and outcomes in children with demyelinating syndromes. JAMA Neurol. (2020) 77:82–93. 10.1001/jamaneurol.2019.2940
6.
ArmangueTCapobiancoMde ChalusALaetitiaGDeivaKE.U. paediatric MOG Consortium. E.U. paediatric MOG consortium consensus: part 3 - biomarkers of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders. Eur J Paediatr Neurol. (2020) 29:22–31. 10.1016/j.ejpn.2020.11.001
7.
KapoorRSmithKEAllegrettaMArnoldDLCarrollWComabellaMet al. Serum neurofilament light as a biomarker in progressive multiple sclerosis. Neurology. (2020) 95:436–44. 10.1212/WNL.0000000000010346
8.
DisantoGBarroCBenkertPNaegelinYSchädelinSGiardielloAet al. Serum Neurofilament light: a biomarker of neuronal damage in multiple sclerosis. Ann Neurol. (2017) 81:857–70. 10.1002/ana.24954
9.
AndersonVBentleyELovelessSBianchiLHardingKEWynford-ThomasRAet al. Serum neurofilament-light concentration and real-world outcome in MS. J Neurol Sci. (2020) 417:117079. 10.1016/j.jns.2020.117079
10.
RossoMHealyBCSaxenaSPaulABjornevikKKuhleJ„et al. MRI lesion state modulates the relationship between serum neurofilament light and age in multiple sclerosis. J Neuroimaging. (2021) 31:388–93. 10.1111/jon.12826
11.
KhalilMTeunissenCEOttoMPiehlFSormaniMPGattringerTet al. Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol. (2018) 14:577–89. 10.1038/s41582-018-0058-z
12.
BarroCChitnisTWeinerHL. Blood neurofilament light: a critical review of its application to neurologic disease. Ann Clin Transl Neurol. (2020) 7:2508–23. 10.1002/acn3.51234
13.
BrunnerCLassmannHWaehneldtTVMatthieuJMLiningtonC. Differential ultrastructural localization of myelin basic protein, myelin/oligodendroglial glycoprotein, and 2',3'-cyclic nucleotide 3'-phosphodiesterase in the CNS of adult rats. J Neurochem. (1989) 52:296–304. 10.1111/j.1471-4159.1989.tb10930.x
14.
MariottoSFarinazzoAMonacoSGajofattoAZanussoGSchandaKet al. Serum neurofilament light chain in NMOSD and related disorders: comparison according to aquaporin-4 and myelin oligodendrocyte glycoprotein antibodies status. Mult Scler J Exp Transl Clin. (2017) 3:2055217317743098. 10.1177/2055217317743098
15.
BrillLGanelin-CohenEDabbyRRabinowiczSZohar-DayanEReinNet al. Age-related clinical presentation of MOG-IgG seropositivity in Israel. Front Neurol. (2020) 11:612304. 10.3389/fneur.2020.612304
16.
GontikaMPAnagnostouliMC. Anti-myelin oligodendrocyte glycoprotein and human leukocyte antigens as markers in pediatric and adolescent multiple sclerosis: on diagnosis, clinical phenotypes, and therapeutic responses. Mult Scler Int. (2018) 2018:8487471. 10.1155/2018/8487471
17.
MariottoSFerrariSGastaldiMFranciottaDSechiECapraRet al. Neurofilament light chain serum levels reflect disease severity in MOG-Ab associated disorders. J Neurol Neurosurg Psychiatry. (2019) 90:1293–6. 10.1136/jnnp-2018-320287
18.
MariottoSGastaldiMGrazianLMancinelliCCapraRMarignierRet al. NfL levels predominantly increase at disease onset in MOG-Abs-associated disorders. Mult Scler Relat Disord. (2021) 50:102833. 10.1016/j.msard.2021.102833
19.
BolloLIaffaldanoPRuggieriMPalazzoCMastrapasquaMManniAet al. Longitudinal evaluation of serum MOG-IgG and AQP4-IgG antibodies in NMOSD by a semiquantitative ratiometric method. Front Neurol. (2021) 12:633115. 10.3389/fneur.2021.633115
20.
PisaniFSparaneoATortorellaCRuggieriMTrojanoMMolaMGet al. Aquaporin-4 autoantibodies in Neuromyelitis Optica: AQP4 isoform-dependent sensitivity and specificity. PloS ONE. (2013) 8:e79185. 10.1371/journal.pone.0079185
21.
KruppLBTardieuMAmatoMPBanwellBChitnisTDaleRCet al. International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions. Mult Scler J. (2013) 19:1261–7. 10.1177/1352458513484547
22.
DuignanSWrightSRossorTCazabonJGilmourKCiccarelliOet al. Myelin oligodendrocyte glycoprotein and aquaporin-4 antibodies are highly specific in children with acquired demyelinating syndromes. Dev Med Child Neurol. (2018) 60:958–62. 10.1111/dmcn.13703
23.
HacohenYAbsoudMDeivaKHemingwayCNytrovaPWoodhallMet al. Myelin oligodendrocyte glycoprotein antibodies are associated with a non-MS course in children. Neurol Neuroimmunol Neuroinflammation. (2015) 2:e81. 10.1212/NXI.0000000000000081
24.
BaumannMSahinKLechnerCHennesEMSchandaKMaderSet al. Clinical and neuroradiological differences of paediatric acute disseminating encephalomyelitis with and without antibodies to the myelin oligodendrocyte glycoprotein. J Neurol Neurosurg Psychiatry. (2015) 86:265–72. 10.1136/jnnp-2014-308346
25.
Cobo-CalvoARuizARollotFArrambideGDeschampsRMaillartEet al. Clinical features and risk of relapse in children and adults with myelin oligodendrocyte glycoprotein antibody-associated disease. Ann Neurol. (2021) 89:30–41. 10.1002/ana.25909
26.
ShahimPDarinNAndreassonUBlennowKJennionsELundgrenJet al. Cerebrospinal fluid brain injury biomarkers in children: a multicenter study. Pediatr Neurol. (2013) 49:31–9.e2. 10.1016/j.pediatrneurol.2013.02.015
27.
PfeifenbringSBunyanRFMetzIRöverCHuppkePGärtnerJet al. Extensive acute axonal damage in pediatric multiple sclerosis lesions. Ann Neurol. (2015) 77:655–67. 10.1002/ana.24364
28.
TakaiYMisuTKanekoKChiharaNNarikawaKTsuchidaSet al. Myelin oligodendrocyte glycoprotein antibody-associated disease: an immunopathological study. Brain J Neurol. (2020) 143:1431–46. 10.1093/brain/awaa102
29.
SergueraCStimmerLFovetCMHorellouPContrerasVTchitchekNet al. Anti-MOG autoantibodies pathogenicity in children and macaques demyelinating diseases. J Neuroinflammation. (2019) 16:244. 10.1186/s12974-019-1637-7
30.
MacriniCGerhardsRWinklmeierSBergmannLMaderSSpadaroMet al. Features of MOG required for recognition by patients with MOG antibody-associated disorders. Brain J Neurol. (2021) 144:2375–89. 10.1093/brain/awab105
Summary
Keywords
serum neurofilament light chain, encephalopathy, myelin oligodendrocyte antibody, pediatric acute demyelinating disease, biomarkers
Citation
Simone M, Palazzo C, Mastrapasqua M, Bollo L, Pompamea F, Gabellone A, Marzulli L, Giordano P, De Giacomo A, Frigeri A, Ruggieri M and Margari L (2021) Serum Neurofilament Light Chain Levels and Myelin Oligodendrocyte Glycoprotein Antibodies in Pediatric Acquired Demyelinating Syndromes. Front. Neurol. 12:754518. doi: 10.3389/fneur.2021.754518
Received
06 August 2021
Accepted
07 October 2021
Published
11 November 2021
Volume
12 - 2021
Edited by
Tanuja Chitnis, Brigham and Women's Hospital and Harvard Medical School, United States
Reviewed by
Eoin Flanagan, Mayo Clinic, United States; Silvia Messina, University of Oxford, United Kingdom
Updates
Copyright
© 2021 Simone, Palazzo, Mastrapasqua, Bollo, Pompamea, Gabellone, Marzulli, Giordano, De Giacomo, Frigeri, Ruggieri and Margari.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Marta Simone marta.simone@uniba.it
This article was submitted to Multiple Sclerosis and Neuroimmunology, a section of the journal Frontiers in Neurology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.